Dare Bioscience, Inc. financial data

Symbol
DARE on Nasdaq
Industry
Pharmaceutical Preparations
Location
3655 Nobel Drive, Suite 260, San Diego, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Cerulean Pharma Inc. (to 7/5/2017), Tempo Pharmaceuticals Inc (to 1/22/2008)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 89.5 % -35.9%
Debt-to-equity -630 % -331%
Return On Equity 184 %
Return On Assets -34.7 % +67.7%
Operating Margin -949 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.55M shares -90.3%
Common Stock, Shares, Outstanding 8.55M shares -90.1%
Entity Public Float 77.3M USD -24.4%
Common Stock, Value, Issued 854 USD -90.1%
Weighted Average Number of Shares Outstanding, Basic 8.41M shares +16.8%
Weighted Average Number of Shares Outstanding, Diluted 8.48M shares +17.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.84M USD
Revenue from Contract with Customer, Excluding Assessed Tax 22.4K USD
Research and Development Expense 18.7M USD -34.4%
General and Administrative Expense 11M USD -9.62%
Operating Income (Loss) -26.9M USD +33.9%
Net Income (Loss) Attributable to Parent -7.2M USD +81.9%
Earnings Per Share, Basic 2.42 USD/shares
Earnings Per Share, Diluted 2.41 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.4M USD +23.2%
Accounts Receivable, after Allowance for Credit Loss, Current 10M USD
Other Assets, Current 152K USD -24.4%
Assets, Current 20.8M USD -6.36%
Property, Plant and Equipment, Net 322K USD +604%
Operating Lease, Right-of-Use Asset 1.45M USD +424%
Other Assets, Noncurrent 529K USD -42.6%
Assets 23.6M USD +1.71%
Accounts Payable, Current 1.91M USD -70.8%
Employee-related Liabilities, Current 805K USD -53.2%
Accrued Liabilities, Current 1.25M USD -70.1%
Contract with Customer, Liability, Current 205K USD
Liabilities, Current 14.6M USD -40.9%
Contract with Customer, Liability, Noncurrent 1M USD -17%
Operating Lease, Liability, Noncurrent 1.04M USD +4344%
Liabilities 20.9M USD -19.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -386K USD +4.68%
Retained Earnings (Accumulated Deficit) -165M USD -4.56%
Stockholders' Equity Attributable to Parent 2.67M USD
Liabilities and Equity 23.6M USD +1.71%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.81M USD +57.7%
Net Cash Provided by (Used in) Financing Activities 14K USD -98.9%
Net Cash Provided by (Used in) Investing Activities -7.3K USD
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 8.55M shares -90.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.85M USD +53.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.7M USD +22.3%
Deferred Tax Assets, Valuation Allowance 112M USD +7.71%
Deferred Tax Assets, Gross 112M USD +7.71%
Operating Lease, Liability 1.53M USD +415%
Depreciation 10.8K USD +13.4%
Payments to Acquire Property, Plant, and Equipment 7.3K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.18M USD +82%
Lessee, Operating Lease, Liability, to be Paid 1.77M USD +477%
Operating Lease, Liability, Current 488K USD +79.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 680K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 660K USD +610%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 242K USD +2320%
Lessee, Operating Lease, Liability, to be Paid, Year Three 130K USD
Deferred Tax Assets, Operating Loss Carryforwards 86.2M USD +5.41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 2.62M USD +13%
Operating Lease, Payments 508K USD +65.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%